Corrado Advisors LLC Trims Stock Holdings in Pfizer Inc. (NYSE:PFE)

Corrado Advisors LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 13.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 61,708 shares of the biopharmaceutical company’s stock after selling 9,515 shares during the period. Corrado Advisors LLC’s holdings in Pfizer were worth $1,777,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. NewSquare Capital LLC increased its stake in Pfizer by 3.0% during the fourth quarter. NewSquare Capital LLC now owns 147,446 shares of the biopharmaceutical company’s stock worth $4,190,000 after purchasing an additional 4,354 shares during the period. Cutter & CO Brokerage Inc. increased its stake in Pfizer by 473.4% during the fourth quarter. Cutter & CO Brokerage Inc. now owns 104,331 shares of the biopharmaceutical company’s stock worth $3,004,000 after purchasing an additional 86,137 shares during the period. GAMMA Investing LLC acquired a new position in Pfizer in the fourth quarter valued at approximately $342,000. Harbor Advisors LLC boosted its holdings in Pfizer by 68.6% in the fourth quarter. Harbor Advisors LLC now owns 31,962 shares of the biopharmaceutical company’s stock valued at $920,000 after purchasing an additional 13,000 shares in the last quarter. Finally, Ellenbecker Investment Group boosted its holdings in Pfizer by 56.2% in the fourth quarter. Ellenbecker Investment Group now owns 13,222 shares of the biopharmaceutical company’s stock valued at $380,000 after purchasing an additional 4,756 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Guggenheim assumed coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a report on Thursday, January 4th. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Eleven analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $36.33.

Pfizer Stock Performance

Shares of NYSE PFE traded up $0.06 during mid-day trading on Tuesday, hitting $26.32. 24,286,365 shares of the company were exchanged, compared to its average volume of 42,105,117. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The stock has a 50 day simple moving average of $27.08 and a 200-day simple moving average of $28.56. Pfizer Inc. has a 1-year low of $25.23 and a 1-year high of $40.37. The firm has a market cap of $149.04 billion, a price-to-earnings ratio of 73.11, a price-to-earnings-growth ratio of 1.17 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. Pfizer’s revenue was down 41.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.14 earnings per share. On average, sell-side analysts forecast that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.